Abstract
AimElevated Interleukin-6 (IL-6) is associated with the pathogenesis of various chronic inflammation and autoimmune conditions.1 Currently, only three IL-6 inhibitors, tocilizumab, siltuximab and sarilumab, are approved for a limited number...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have